Drug Manufacturers - Specialty & Generic
Compare Stocks
4 / 10Stock Comparison
IRWD vs CPIX vs SUPN vs PRGO
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
IRWD vs CPIX vs SUPN vs PRGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $680M | $65M | $3.01B | $1.61B |
| Revenue (TTM) | $362M | $42M | $777M | $4.18B |
| Net Income (TTM) | $151M | $-7M | $-29M | $-1.82B |
| Gross Margin | 70.4% | 82.9% | 89.4% | 34.2% |
| Operating Margin | 55.3% | -17.2% | -5.5% | -4.1% |
| Forward P/E | 3.1x | — | 24.1x | 5.6x |
| Total Debt | $598M | $10M | $41M | $3.97B |
| Cash & Equiv. | $215M | $11M | $128M | $532M |
IRWD vs CPIX vs SUPN vs PRGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Ironwood Pharmaceut… (IRWD) | 100 | 42.9 | -57.1% |
| Cumberland Pharmace… (CPIX) | 100 | 130.7 | +30.7% |
| Supernus Pharmaceut… (SUPN) | 100 | 216.7 | +116.7% |
| Perrigo Company plc (PRGO) | 100 | 21.4 | -78.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IRWD vs CPIX vs SUPN vs PRGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
IRWD carries the broadest edge in this set and is the clearest fit for value and quality.
- Lower P/E (3.1x vs 5.6x)
- 41.8% margin vs PRGO's -43.5%
- +426.5% vs PRGO's -51.2%
- 38.5% ROA vs PRGO's -19.8%, ROIC 54.0% vs 3.7%
CPIX is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 17.6%, EPS growth 58.7%, 3Y rev CAGR 2.0%
- 17.6% revenue growth vs IRWD's -15.7%
SUPN is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.78
- 228.4% 10Y total return vs CPIX's -8.1%
- Lower volatility, beta 0.78, Low D/E 3.9%, current ratio 1.90x
- Beta 0.78, current ratio 1.90x
PRGO is the clearest fit if your priority is dividends.
- 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 17.6% revenue growth vs IRWD's -15.7% | |
| Value | Lower P/E (3.1x vs 5.6x) | |
| Quality / Margins | 41.8% margin vs PRGO's -43.5% | |
| Stability / Safety | Beta 0.78 vs IRWD's 2.50 | |
| Dividends | 9.8% yield; 10-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +426.5% vs PRGO's -51.2% | |
| Efficiency (ROA) | 38.5% ROA vs PRGO's -19.8%, ROIC 54.0% vs 3.7% |
IRWD vs CPIX vs SUPN vs PRGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
IRWD vs CPIX vs SUPN vs PRGO — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
IRWD leads in 2 of 6 categories
PRGO leads 1 • CPIX leads 1 • SUPN leads 1
Explore the data ↓Income & Cash Flow (Last 12 Months)
IRWD leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO is the larger business by revenue, generating $4.2B annually — 99.6x CPIX's $42M. IRWD is the more profitable business, keeping 41.8% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, IRWD holds the edge at +158.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $362M | $42M | $777M | $4.2B |
| EBITDAEarnings before interest/tax | $201M | -$4M | $29M | $58M |
| Net IncomeAfter-tax profit | $151M | -$7M | -$29M | -$1.8B |
| Free Cash FlowCash after capex | $112M | $1M | $82M | $108M |
| Gross MarginGross profit ÷ Revenue | +70.4% | +82.9% | +89.4% | +34.2% |
| Operating MarginEBIT ÷ Revenue | +55.3% | -17.2% | -5.5% | -4.1% |
| Net MarginNet income ÷ Revenue | +41.8% | -17.6% | -3.7% | -43.5% |
| FCF MarginFCF ÷ Revenue | +31.0% | +3.2% | +10.6% | +2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +158.9% | -22.0% | +38.6% | -7.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.0% | -3.8% | +81.0% | -56.4% |
Valuation Metrics
PRGO leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than SUPN's 53.4x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $680M | $65M | $3.0B | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $1.1B | $63M | $2.9B | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | 27.80x | -22.77x | -76.88x | -1.14x |
| Forward P/EPrice ÷ next-FY EPS est. | 3.14x | — | 24.12x | 5.56x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 8.81x | 25.44x | 53.44x | 7.42x |
| Price / SalesMarket cap ÷ Revenue | 2.30x | 1.45x | 4.19x | 0.38x |
| Price / BookPrice ÷ Book value/share | — | 2.64x | 2.78x | 0.55x |
| Price / FCFMarket cap ÷ FCF | 5.35x | 13.39x | 65.45x | 11.12x |
Profitability & Efficiency
IRWD leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
SUPN delivers a -2.7% return on equity — every $100 of shareholder capital generates $-3 in annual profit, vs $-51 for PRGO. SUPN carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), IRWD scores 6/9 vs PRGO's 4/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -29.7% | -2.7% | -50.7% |
| ROA (TTM)Return on assets | +38.5% | -10.5% | -2.0% | -19.8% |
| ROICReturn on invested capital | +54.0% | -8.6% | -2.8% | +3.7% |
| ROCEReturn on capital employed | +50.9% | -6.6% | -3.4% | +4.3% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 4 | 4 |
| Debt / EquityFinancial leverage | — | 0.41x | 0.04x | 1.35x |
| Net DebtTotal debt minus cash | $382M | -$1M | -$87M | $3.4B |
| Cash & Equiv.Liquid assets | $215M | $11M | $128M | $532M |
| Total DebtShort + long-term debt | $598M | $10M | $41M | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | 8.43x | -27.86x | — | -7.20x |
Total Returns (Dividends Reinvested)
CPIX leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SUPN five years ago would be worth $17,801 today (with dividends reinvested), compared to $3,800 for IRWD. Over the past 12 months, IRWD leads with a +426.5% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors CPIX at 37.1% vs IRWD's -26.5% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -2.3% | +8.7% | +5.7% | -13.5% |
| 1-Year ReturnPast 12 months | +426.5% | -2.1% | +69.0% | -51.2% |
| 3-Year ReturnCumulative with dividends | -60.3% | +157.6% | +42.1% | -58.1% |
| 5-Year ReturnCumulative with dividends | -62.0% | +62.7% | +78.0% | -60.1% |
| 10-Year ReturnCumulative with dividends | -59.2% | -8.1% | +228.4% | -77.7% |
| CAGR (3Y)Annualised 3-year return | -26.5% | +37.1% | +12.4% | -25.2% |
Risk & Volatility
SUPN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
SUPN is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than IRWD's 2.50 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SUPN currently trades 87.6% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.50x | 1.09x | 0.78x | 1.18x |
| 52-Week HighHighest price in past year | $5.78 | $6.27 | $59.68 | $28.44 |
| 52-Week LowLowest price in past year | $0.53 | $1.85 | $29.16 | $9.23 |
| % of 52W HighCurrent price vs 52-week peak | +72.1% | +69.0% | +87.6% | +41.2% |
| RSI (14)Momentum oscillator 0–100 | 68.4 | 67.9 | 57.9 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 2.5M | 1.2M | 604K | 3.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: IRWD as "Hold", SUPN as "Buy", PRGO as "Hold". Consensus price targets imply 70.6% upside for PRGO (target: $20) vs 14.8% for SUPN (target: $60). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | — | Buy | Hold |
| Price TargetConsensus 12-month target | $4.80 | — | $60.00 | $20.00 |
| # AnalystsCovering analysts | 30 | — | 14 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +9.8% |
| Dividend StreakConsecutive years of raises | — | — | — | 10 |
| Dividend / ShareAnnual DPS | — | — | — | $1.15 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.4% | 0.0% | 0.0% |
IRWD leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 1 (Valuation Metrics).
IRWD vs CPIX vs SUPN vs PRGO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is IRWD or CPIX or SUPN or PRGO a better buy right now?
For growth investors, Cumberland Pharmaceuticals Inc.
(CPIX) is the stronger pick with 17. 6% revenue growth year-over-year, versus -15. 7% for Ironwood Pharmaceuticals, Inc. (IRWD). Ironwood Pharmaceuticals, Inc. (IRWD) offers the better valuation at 27. 8x trailing P/E (3. 1x forward), making it the more compelling value choice. Analysts rate Supernus Pharmaceuticals, Inc. (SUPN) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — IRWD or CPIX or SUPN or PRGO?
On forward P/E, Ironwood Pharmaceuticals, Inc.
is actually cheaper at 3. 1x.
03Which is the better long-term investment — IRWD or CPIX or SUPN or PRGO?
Over the past 5 years, Supernus Pharmaceuticals, Inc.
(SUPN) delivered a total return of +78. 0%, compared to -62. 0% for Ironwood Pharmaceuticals, Inc. (IRWD). Over 10 years, the gap is even starker: SUPN returned +228. 4% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — IRWD or CPIX or SUPN or PRGO?
By beta (market sensitivity over 5 years), Supernus Pharmaceuticals, Inc.
(SUPN) is the lower-risk stock at 0. 78β versus Ironwood Pharmaceuticals, Inc. 's 2. 50β — meaning IRWD is approximately 219% more volatile than SUPN relative to the S&P 500. On balance sheet safety, Supernus Pharmaceuticals, Inc. (SUPN) carries a lower debt/equity ratio of 4% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
05Which is growing faster — IRWD or CPIX or SUPN or PRGO?
By revenue growth (latest reported year), Cumberland Pharmaceuticals Inc.
(CPIX) is pulling ahead at 17. 6% versus -15. 7% for Ironwood Pharmaceuticals, Inc. (IRWD). On earnings-per-share growth, the picture is similar: Cumberland Pharmaceuticals Inc. grew EPS 58. 7% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, SUPN leads at 2. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — IRWD or CPIX or SUPN or PRGO?
Ironwood Pharmaceuticals, Inc.
(IRWD) is the more profitable company, earning 8. 1% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 8. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IRWD leads at 40. 1% versus -6. 3% for CPIX. At the gross margin level — before operating expenses — IRWD leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is IRWD or CPIX or SUPN or PRGO more undervalued right now?
On forward earnings alone, Ironwood Pharmaceuticals, Inc.
(IRWD) trades at 3. 1x forward P/E versus 24. 1x for Supernus Pharmaceuticals, Inc. — 21. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.
08Which pays a better dividend — IRWD or CPIX or SUPN or PRGO?
In this comparison, PRGO (9.
8% yield) pays a dividend. IRWD, CPIX, SUPN do not pay a meaningful dividend and should not be held primarily for income.
09Is IRWD or CPIX or SUPN or PRGO better for a retirement portfolio?
For long-horizon retirement investors, Supernus Pharmaceuticals, Inc.
(SUPN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 78), +228. 4% 10Y return). Ironwood Pharmaceuticals, Inc. (IRWD) carries a higher beta of 2. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SUPN: +228. 4%, IRWD: -59. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between IRWD and CPIX and SUPN and PRGO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: IRWD is a small-cap quality compounder stock; CPIX is a small-cap high-growth stock; SUPN is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while IRWD, CPIX, SUPN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.